Press Releases

HONG KONG, June 13, 2017 — On June 13, 2017, WuXi Biologics (Cayman) Inc. (“the Company”; stock code: 2269.HK) was officially listed during a grand listing ceremony at the Main Board of The Stock Exchange of Hong Kong. Dr. Ge Li,Chairman of WuXi Biologics, Dr. Chris Chen,CEO of WuXi Biologics, and representatives from the Company, its intermediary institutions, and its collaborative partners, witnessed this important development milestone of the Company.

Headquartered in Wuxi city, Jiangsu province, with three operation sites in Wuxi, Shanghai and Suzhou respectively, WuXi Biologics is a leading global open-access biologics capability and technology enabling platform in the world with end-to-end solutions, empowering anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing.

“The successful listing of WuXi Biologics on the Hong Kong Stock Exchange marks another important milestone in the history of the Company,” said Dr. Ge Li. “This will further accelerate our expansion in capabilities and capacities, strengthen our leadership position as the most comprehensive and integrated enabling platform, and will allow us to better enable innovation to benefit patients worldwide.”

“The successful listing on the Main Board of the Stock Exchange of Hong Kong is a new starting point for WuXi Biologics,” said Dr. Chris Chen. “We will further standardize the operation and management of the Company, strictly abide by the Listing Rules, and diligently fulfill various regulatory obligations as a public company. We will reciprocate the trust of our collaborative partners, investors, and employees with strong performance, sustainable growth, and value for patients and society.”

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore and US exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.